Brief: SAB Biotherapeutics Inc Says It Will Submit IND Filing Within About 12 Months
10/01/2023 13:13
Jan 10 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS INC - WILL SUBMIT IND FILING WITHIN
APPROXIMATELY 12 MONTHS
* SAB BIOTHERAPEUTICS SUCCESSFULLY CONCLUDES IND-ENABLING
GLP
TOXICOLOGY STUDY FOR SAB-142, A NOVEL IMMUNOTHERAPEUTIC FOR TYPE
1 DIABETES
* SAB BIOTHERAPEUTICS INC - STUDY FOUND SAB-142 TO BE WELL
TOLERATED
Source text for Eikon: ID:nGNX2hjf16
Further company coverage: SABS.O
((reuters.briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies